Open Medicine Foundation

OMF is fundraising to support open, collaborative research to find effective treatments and diagnostic markers for ME/CFS, Long COVID, and related diseases.

[Open Medicine Foundation @OpenMedF]

The investigation tries to understand how POTS contributes to variations in the disease.

Read more about the study here: https://t.co/2lGXZCmJhw

[Open Medicine Foundation @OpenMedF]

🧬Science Wednesdays: Differential expression

Differential expression is a way of looking at differences in protein levels (gene expression) between groups.

[Open Medicine Foundation @OpenMedF]

At OMF’s Collaborative Center at Uppsala, the team has utilized differential expression analysis on proteomics data collected on cerebrospinal fluid samples from people with ME/CFS with and without postural orthostatic tachycardia syndrome (POTS).

[Open Medicine Foundation @OpenMedF]

OMF’s large-scale biomarker project, BioQuest, is working to incorporate subtype identification into its study. Read more about the project on our website: https://t.co/ebR339ufm0.

#MECFS

[Open Medicine Foundation @OpenMedF]

🧬Science Wednesdays: Subtyping

Subtyping is the act of identifying smaller groups within a larger group of people. In the context of disease, subtypes are typically variations of the larger disease (e.g., HER2+ breast cancer is a subtype of breast cancer).

[Open Medicine Foundation @OpenMedF]

As ME/CFS is a heterogeneous disease, it’s likely that there are subtypes of the disease to identify. Subtyping might be particularly important for helping guide treatments.

[Open Medicine Foundation @OpenMedF]

As May Momentum comes to a close, we want to leave you with a taste of why our researchers do what they do.

Watch the full conversation here: https://t.co/xbdDV0w7Jt

[Open Medicine Foundation @OpenMedF]

Today at the Invest in ME Conference, Dr. Maureen Hanson — member of OMF's Scientific Advisory Board — presented "Searching for Chronic Infection in ME."

Thank you, Dr. Hanson, for the research that moves us closer to answers for the millions living with ME/CFS.

[Open Medicine Foundation @OpenMedF]

Read more about the trial on our website: https://t.co/4cDblSd5rf.

[Open Medicine Foundation @OpenMedF]

🧬Science Wednesdays: Autonomic nervous system

The autonomic nervous system controls involuntary actions in the body like heart rate, blood pressure, digestion, and more.

[Open Medicine Foundation @OpenMedF]

OMF’s clinical trial, the Life Improvement Trial (LIFT), is investigating two drugs:pyridostigmine and low-dose naltrexone. Pyridostigmine has been used off-label to manage dysautonomia, so the LIFT may, in part, help to address dysautonomia in ME/CFS.

[Janet Dafoe @JanetDafoe]

We are excited to be going to the Invest In ME conference outside of Cambridge England again this year. Ron Davis and Rob Phair, are both going to be speakers. I will be doing my usual schmoozing around with all the researchers!

[Open Medicine Foundation @OpenMedF]

OMF’s Melbourne ME/CFS Collaboration has made strides toward developing a diagnostic algorithm for ME/CFS. Read more about it, including the sensitivity and specificity of the algorithm in the paper: https://t.co/N2cU3O4IAL.

[Open Medicine Foundation @OpenMedF]

🧬Science Wednesdays: Sensitivity vs specificity

Sensitivity and specificity are terms that describe how good something is at correctly identifying a condition (e.g., people within a population that have a disease).

[Open Medicine Foundation @OpenMedF]

In ME/CFS research, sensitivity and specificity particularly come into play when trying to develop a diagnostic tool. Currently, there is no objective way to diagnose ME/CFS, so a diagnostic tool that is both sensitive and specific is crucial.

[Open Medicine Foundation @OpenMedF]

Linda Tannenbaum, Founder and CEO of OMF, will deliver the inaugural lecture of Faculty of Medicine of the University of Lisbon’s new Open Lectures series on May 25.